Axceler8 Solutions
Category: AI in Healthcare
Axceler8 Solutions develops and operates digital and AI-powered platforms. Its debut product, Axceler8 Rx, is a cloud-based solution designed to optimize clinical trial design, site selection, and patient enrollment for the pharmaceutical industry. Axceler8 Solutions was founded in 2025. The company is led by Ignacio Garcia Alves. Based in New York, USA. Team size: 2-10 employees. Total funding raised: Undisclosed (Corporate Joint Venture). Latest round: Joint Venture, Undisclosed, 2024-12, led by Arthur D. Little. Key investors include Arthur D. Little, Vega IT.
- Founded
- 2025
- Headquarters
- New York, USA
- Team size
- 2-10 employees
- Total funding
- Undisclosed (Corporate Joint Venture)
Value proposition
Combines Arthur D. Little's strategic clinical trial IP with Vega IT's rapid engineering capabilities to deliver 'strategy-led execution', accelerating time-to-market for digital products.
Products and solutions
Axceler8 Rx, DataSpeak
Unique value
A unique Joint Venture structure that bridges the gap between high-level strategy consulting (ADL) and high-performance software engineering (Vega IT) within a single entity.
Target customer
Pharmaceutical Sponsors and Clinical Research Organizations (CROs)
Industries served
Pharmaceuticals, Life Sciences, Healthcare
Technology advantage
Uses a modular, sector-agnostic architectural approach allowing for faster adaptation and deployment compared to legacy monolithic systems.
How they differentiate
Axceler8 differentiates through its agility and the integration of strategic IP directly into the software development lifecycle, avoiding the disconnect often found between strategy definition and technical execution.
Main competitors
IQVIA, Veeva Systems, Medidata (Dassault Systèmes)
Key partnerships
Arthur D. Little, Vega IT
Notable customers
Pharmaceutical Sponsors, Clinical Research Organizations (CROs)
Major milestones
Official Joint Venture formation announced in December 2024, Launch of debut product 'Axceler8 Rx' for clinical trial optimization
Growth metrics
Launched with immediate product availability (Axceler8 Rx); supported by Vega IT's workforce of 900+ engineers.
Market positioning
Specialized Pharma-Tech Challenger / Boutique Digital Venture
Geographic focus
Global (North America, Europe, Middle East)
Patents and IP
N/A
About Ignacio Garcia Alves
Ignacio Garcia Alves is the Global Chairman and Chief Executive Officer of Arthur D. Little (ADL). He has led ADL since 2011, orchestrating its successful management buyout and re-establishing it as a top-tier global consultancy. With over 30 years of experience, he specializes in linking strategy, innovation, and technology. He co-launched Axceler8 Solutions in 2024 to combine ADL's strategic expertise with Vega IT's engineering capabilities.
Official website: https://axceler8solutions.com/